99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of PTLA Investors. Click "Join this Class Action" above.

Attorneys

Portola Pharmaceuticals, Inc.

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) from November 5, 2019 through January 9, 2020 (the “Class Period”). The lawsuit seeks to recover damages for Portola Pharmaceuticals, Inc. investors under the federal securities laws.

If you bought Portola Pharmaceuticals, Inc. securities between November 5, 2019 through January 9, 2020, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Portola Pharmaceuticals, Inc. – PTLA

New York, N.Y., January 21, 2020. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Portola Pharmaceuticals, Inc.(NASDAQ: PTLA) between November 5, 2019 and January 9,2020, inclusive (the “Class Period”).

To join the PTLA class action, go to http://zhanginvestorlaw.com/cases/portola-pharmaceuticals-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU NEED NOT BE A LEAD PLAINTIFF IN ORDER TO OBTAIN A RECOVERY.

According to the lawsuit, throughout the Class Period (1) Portola’s internal control over financial reporting regarding reserve for product returns was not effective; (2) Portola was shipping longer-dated product with 36-month shelf life; (3) Portola had not established adequate reserve for returns of prior shipments of short-dated product; (4) as a result, Portola was reasonably likely to need to “catch up” on accounting for return reserves; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/portola-pharmaceuticals-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.